<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546857</url>
  </required_header>
  <id_info>
    <org_study_id>2011001012</org_study_id>
    <nct_id>NCT01546857</nct_id>
  </id_info>
  <brief_title>Effect of Gabapentin on Orthopedic Pain</brief_title>
  <official_title>The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if a drug called gabapentin helps in the postoperative&#xD;
      management of patients undergoing hip and knee operations. The investigators wish to&#xD;
      determine the effect of gabapentin on pain and sleep following surgery. If we can lessen a&#xD;
      patient's pain and improve sleep, the patient will be better able to participate in their&#xD;
      physical therapy. Gabapentin has already been shown to lessen postoperative pain when given&#xD;
      before surgery. In healthy patients, it has also been shown to improve certain aspects of&#xD;
      sleep. We hope to identify the effect of the drug, when given after surgery, on patients'&#xD;
      pain and sleep.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have also supported the use of gabapentin as an adjuvant medication in&#xD;
      postoperative pain management. Gabapentin decreased the pain associated with movement in&#xD;
      post-mastectomy patients. Gilron et al showed a combination of gabapentin and rofecoxib&#xD;
      superior to either medication alone in relieving pain after hysterectomy. Later, Gilron et al&#xD;
      showed that adding meloxicam to gabapentin in patients undergoing outpatient laparoscopic&#xD;
      surgery provided little additional benefit. Clarke et al demonstrated the decrease in the use&#xD;
      of opioids in patients who received preoperative and postoperative gabapentin after total&#xD;
      knee arthroplasty. They also noted that optimum timing and dosage of the gabapentin needed to&#xD;
      be further elucidated. However, in the same year, Clarke et al also reported that gabapentin&#xD;
      provided no benefit after total hip arthroplasty when a robust multimodal analgesic regimen&#xD;
      was combined with spinal anesthesia. The side effects of gabapentin include sleepiness, which&#xD;
      may be of benefit in the postoperative period. In a meta-analysis, Peng showed a 35 %&#xD;
      decrease in total opioid consumption in the first 24 hours postoperatively. However, they did&#xD;
      note an increase in sleepiness and dizziness. While a recent investigation did not find a&#xD;
      connection between sleep disturbances and postoperative pain, a questionnaire study found&#xD;
      that the most common reason for nighttime awakenings was pain, and that analgesia was the&#xD;
      most helpful intervention. Gabapentin, a structural analogue to y-aminobutyric acid, has been&#xD;
      shown in healthy subjects to increase SWS; maintain a stable REM; and reduce arousals,&#xD;
      awakenings, and stage shifts-all of which are features of sleep fragmentation. Gabapentin is&#xD;
      currently used to treat epilepsy, diabetic neuropathy, postherpetic neuralgia, as well as&#xD;
      restless legs syndrome, and its effect on sleep patterns may attribute to its therapeutic&#xD;
      success with these disorders Sleep deviates from the normal sleeping pattern in the&#xD;
      postoperative patient. Total sleep time, proportion of REM sleep, and proportion of slow wave&#xD;
      sleep (SWS) are all reduced. Sleep postoperatively tends to be highly fragmented with&#xD;
      multiple spontaneous awakenings and movement arousals. Most of these changes occur during&#xD;
      postoperative days 1 and 2; however, patients also incur a REM sleep rebound in days 3 and 4&#xD;
      that can extend up to a week. Studies have demonstrated that these postoperative sleep&#xD;
      disturbances, notably the prolonged REM sleep rebound, may contribute to the development of&#xD;
      altered mental function, postoperative episodic hypoxemia, and hemodynamic instability. A&#xD;
      recent study even found that postoperative sleep disruptions independently predicted&#xD;
      functional limitations three months following surgery in patients who underwent total knee&#xD;
      replacement. The pathogenesis of these sleep changes appears to be strongly correlated to the&#xD;
      magnitude of the surgery as opposed to the type of anesthesia used. Many specific mediators&#xD;
      of surgical stress response have been indicated, including catecholamines, cortisol, and&#xD;
      IL-1; however, as REM sleep is controlled by many regions of the brain, disturbances may be&#xD;
      due to a global excitatory CNS effect.&#xD;
&#xD;
      Our study will recruit 90 patients between the ages of 18 and 70 who are undergoing total hip&#xD;
      arthroplasty, hip fracture repair, or total knee arthroplasty and have been assigned an ASA&#xD;
      rating of I-III, who are not pregnant. After Institutional Review Board approval, a written&#xD;
      informed consent will be obtained from the patient. The study protocol, use of the Patient&#xD;
      Controlled Analgesia (PCA) pump, sleep scale, sedation scale, and visual analogue scale for&#xD;
      pain will all be explained. Demographic information will be obtained including age, gender,&#xD;
      past medical history, past surgical history, hospitalizations, current medications,&#xD;
      allergies, and history of drug and alcohol abuse. In addition, a preoperative sleep history&#xD;
      will be obtained using the Pittsburgh Sleep Quality Index (PSQI) [14, 15]. The 50 patients&#xD;
      will be randomized into two groups: (1) placebo, (2) gabapentin. An Excel generated&#xD;
      randomization schedule will be employed. The dosage of gabapentin administered will be 400mg.&#xD;
&#xD;
      Prior to surgery, all patients will be administered midazolam 1-3mg IV to achieve anxiolysis.&#xD;
      They will also receive a lumbar plexus block or a femoral nerve block, depending on the&#xD;
      surgery to be done, as this has become the standard of care for orthopedic patients at&#xD;
      University Hospital. All patients will receive celecoxib 200 mg po bid for three&#xD;
      postoperative days. In the operating room, standard general anesthesia technique will be&#xD;
      utilized. Upon extubation, the patient will be transferred to the postanesthesia care unit&#xD;
      (PACU), where baseline pain and sedation scores will be obtained using the Visual Acuity&#xD;
      Scale (VAS), the Richmond Agitation Sedation Scale (RASS), and Ramsay Sedation Scale (RSS),&#xD;
      respectively. All pain scores will be assessed with subjects in the resting position. A&#xD;
      continuous infusion of bupivacaine 0.125mg/L will be started at a rate of 10mL/hr and&#xD;
      continued to postoperative day 2. An I.V. PCA hydromorphone pump will be initiated and set to&#xD;
      deliver a 0.2mg bolus per demand with a 5 minute lockout and no background infusion. All&#xD;
      patients will be instructed to maintain their VAS pain score at less than 4 out of 10. If the&#xD;
      VAS pain score is 5 or greater at rest on two consecutive pain assessments, the dose of&#xD;
      intravenous PCA hydromorphone will be increased to deliver a 0.3mg bolus per demand.&#xD;
&#xD;
      At approximately 9pm on the day of the procedure the first dose of placebo/gabapentin will be&#xD;
      given. The gabapentin or placebo treatment will be given once more at 9 pm on postoperative&#xD;
      day 1. The surgical team will be asked not to order any additional medication for sleep. The&#xD;
      following mornings, on POD1 and POD2, a questionnaire addressing the quality of sleep, hours&#xD;
      of sleep, number of awakenings throughout the night, and contributing reasons for these&#xD;
      awakenings (pain, noise, urination, temperature discomfort, positional discomfort, for&#xD;
      nursing care, or other reasons) will be given. Patients will also be assessed for pain,&#xD;
      sedation, as well as the incidence of any side effects, including nausea, vomiting,&#xD;
      dizziness, and pruritus. In addition, all patients will begin an as-tolerated weight-bearing&#xD;
      rehabilitation program for range of motion, strengthening, balance and ambulation beginning&#xD;
      the first day after surgery. Success in completion of the physical therapy goals of being out&#xD;
      of bed in a chair by postop day 1 and ambulating by postop day 2 will be determined for each&#xD;
      group.&#xD;
&#xD;
      The purpose of this study is to determine if a single dose of gabapentin decrease patients'&#xD;
      postoperative pain. The primary endpoint will be opioid consumption; additional assessments&#xD;
      will include: subjective sleep scales, pain scores, and patient's ability to reach&#xD;
      postoperative rehabilitation goals&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No longer able to recruit subjects due to unavailability of orthopedic surgeon.&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Sleep.</measure>
    <time_frame>Night of surgery (POD 1) and Postoperative Day 2.(POD 2)</time_frame>
    <description>A questionnaire was administered asking participants about the quality of their sleep on the night of surgery asked on postoperative day 1, and on the first postoperative night ( POD 2) . Scored on a scale of zero to 3. Zero meaning poor postoperative sleep and 3 indicating better postoperative sleep.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>48 hours post operatively</time_frame>
    <description>Patient Controlled Analgesia use over 48 hours reported in Morphine equivalent dosage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for Pain</measure>
    <time_frame>48 hours post operatively</time_frame>
    <description>Severity of pain measure on a scale from zero to ten. Zero no pain to ten severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reaching Rehab Goals.</measure>
    <time_frame>Duration of hospital stay up to 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Degenerative Arthritis and Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo one dose in the evening of surgery and post op day #1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gapabentin</intervention_name>
    <description>400mg orally at 9pm day of surgery and the first evening post operatively.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing a hip arthroplasty, total knee arthroplasty, hip fracture repair American&#xD;
             Society of Anesthesiologist rating I-III as determined by your anesthesiologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
               -  An allergy to any of the drugs to be used in the study (midazolam, Celecoxib,&#xD;
                  gabapentin, hydromorphone, bupivacaine)&#xD;
&#xD;
               -  History of a sleep disorder (Obstructive sleep apnea or daytime somnolence)&#xD;
&#xD;
               -  History of taking chronic narcotic pain medications or gabapentin&#xD;
&#xD;
               -  History of rheumatoid arthritis, a psychiatric disorder, or diabetes with&#xD;
                  impaired renal function&#xD;
&#xD;
               -  History of alcohol or illicit drug abuse.&#xD;
&#xD;
               -  History of a kidney or liver problem.&#xD;
&#xD;
               -  Inability or unwilling to use patient-controlled analgesia.&#xD;
&#xD;
               -  Unable to meet the criteria for removal of the endotracheal tube in the Operating&#xD;
                  Room&#xD;
&#xD;
               -  History of asthma, hives or an allergic type reaction following an aspirin or&#xD;
                  other NSAIDS drug such as Ibuprofen.&#xD;
&#xD;
               -  History of stroke or heart attack or thrombotic event within the past 3 months&#xD;
&#xD;
               -  Lactose intolerance&#xD;
&#xD;
               -  History of cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Daniel Eloy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers/SUNJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28348503</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <results_first_submitted>March 14, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 19, 2021</results_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Jean Daniel Eloy, MD</investigator_full_name>
    <investigator_title>J. Daniel Eloy, MD Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>orthopedic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin</title>
          <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>we enrolled 34 patients, however 5 subjects withdrew fro the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Gabapentin</title>
          <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>We enrolled 34 subjects but 5 withdrew from the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.33" lower_limit="48" upper_limit="60"/>
                    <measurement group_id="B2" value="54.6" lower_limit="50" upper_limit="64"/>
                    <measurement group_id="B3" value="54.1" lower_limit="48" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>34 subject were enrolled but 5 withdrew from the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Number of participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Class</title>
          <description>Anesthesiology Physical Status for disease severity with ASA 1 classifying healthy subject and ASA 3 specifying more disease severity.</description>
          <population>34 subjects were enrolled but 5 withdrew from the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pittsburgh Sleep Quality Index</title>
          <description>PSQI is a self-rating questionnaire used to measure the quality and other parameters of sleep in adults. The PSQI is comprised of seven categories which are graded and equally weighed on a scale from&quot;0&quot; to &quot;3&quot; with the value of &quot;3&quot; being the most negative endpoint. The categories are subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The seven components are added up to a global score which ranges between &quot;0&quot; and &quot;21&quot; with higher scores indicating worse sleep quality.</description>
          <population>while we enrolled 34 subjects, 5 withdrew from the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.333" spread="4.355"/>
                    <measurement group_id="B2" value="6.765" spread="3.562"/>
                    <measurement group_id="B3" value="7.0" spread="3.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Sleep.</title>
        <description>A questionnaire was administered asking participants about the quality of their sleep on the night of surgery asked on postoperative day 1, and on the first postoperative night ( POD 2) . Scored on a scale of zero to 3. Zero meaning poor postoperative sleep and 3 indicating better postoperative sleep.</description>
        <time_frame>Night of surgery (POD 1) and Postoperative Day 2.(POD 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Sleep.</title>
          <description>A questionnaire was administered asking participants about the quality of their sleep on the night of surgery asked on postoperative day 1, and on the first postoperative night ( POD 2) . Scored on a scale of zero to 3. Zero meaning poor postoperative sleep and 3 indicating better postoperative sleep.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POD 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.333" spread="0.651"/>
                    <measurement group_id="O2" value="1.235" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.853"/>
                    <measurement group_id="O2" value="0.647" spread="0.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Opioid Consumption</title>
        <description>Patient Controlled Analgesia use over 48 hours reported in Morphine equivalent dosage.</description>
        <time_frame>48 hours post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Patient Controlled Analgesia use over 48 hours reported in Morphine equivalent dosage.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.88" spread="6.3"/>
                    <measurement group_id="O2" value="11.02" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale for Pain</title>
        <description>Severity of pain measure on a scale from zero to ten. Zero no pain to ten severe pain.</description>
        <time_frame>48 hours post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale for Pain</title>
          <description>Severity of pain measure on a scale from zero to ten. Zero no pain to ten severe pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="2.28"/>
                    <measurement group_id="O2" value="4.38" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reaching Rehab Goals.</title>
        <time_frame>Duration of hospital stay up to 48 hours</time_frame>
        <population>These data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reaching Rehab Goals.</title>
          <population>These data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo one dose in the evening of surgery and post op day #1.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin</title>
          <description>Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively&#xD;
Gapabentin: 400mg orally at 9pm day of surgery and the first evening post operatively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean Daniel Eloy</name_or_title>
      <organization>Rutgers-New Jersey Medical School</organization>
      <phone>9739721470 ext 973</phone>
      <email>eloyje@njms.rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

